A clinical research consortium sponsored by NIAID and JDRF
The ITN is currently seeking Concept Proposals for novel clinical trials designed to induce immune tolerance in Type 1 Diabetes, transplantation, autoimmune diseases, and allergy and asthma. In addition the ITN accepts applications for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate biomarkers of immune tolerance and investigating the mechanisms of clinical tolerance. Proposals should be submitted via our site: www.immunetolerance.org/submi-a-proposal
Detailed information and instructions: RFP - Clinical Trials in Immune Tolerance
The ITN is currently seeking Concept Proposals for novel clinical trials designed to induce immune tolerance in combined allogeneic solid organ transplantation plus therapeutic cell transfer. The specific criteria and instructions for preparing proposals are in the following RFP:
Deadline: August 31, 2011
Detailed Information and Instructions: RFP – Allogeneic Solid Organ Transplantation Plus Therapeutic Cell Transfer
-------------------
The ITN is currently seeking Concept Proposals for novel clinical trials designed to induce immune tolerance in Rheumatologic Disorders and other areas of Autoimmune Disease.
Detailed Information and Instructions: RFP - Clinical Trials in Rheumatologic Diseases
---------------------
The Immune Tolerance Network (ITN) is seeking ‘Proposal Outlines' for novel clinical trials designed to induce immune tolerance in psoriasis and other autoimmune skin disorders, including those mediated by autoantibodies such as pemphigus and pemphigoid.
DEADLINE: 30 August 2009
Detailed information and instructions: ITN_Psoriasis_RFP_2009.08.30.pdf
-------------------The purpose of this EOI is to gather information from the scientific community about novel ideas for tolerogenic immunotherapeutic trials in type 1 diabetes (T1D). Expressions of interest should be submitted as attached pdf files via e-mail to Philip Bernstein (pbernstein@immunetolerance.org) under the subject line “EOI-Innovative T1D Trials” no later than April 13, 2009 at noon EST.
> Download pdf [72 kb]
